GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron...(-containingmolecules to guide rational d...)

Date:10/8/2007

-containing molecules to guide rational drug design. As a consequence of boron's unique properties, boron containing molecules may access different chemical space than traditional anti-infectives, providing opportunities for structural and biological novelty. Anacor's proprietary technological advances in the synthesis of boron-based compounds coupled with its rational drug design expertise, has enabled the company to rapidly create diverse families of boron-based compounds.

"We are pleased that GlaxoSmithKline, an industry leader in the development and commercialization of anti-infective drugs has acknowledged the potential of our boron-based chemistry for systemic applications," said David Perry, President and Chief Executive Officer. "This agreement with GlaxoSmithKline is consistent with our strategy to maximize the value of our technology platform by forming early collaborations for systemic applications of our boron technology, while developing topical products on our own to a more advanced stage."

"GlaxoSmithKline recently created a single Centre of Excellence for Drug Discovery dedicated to Infectious Diseases," said Zhi Hong, Senior Vice President and Head of GlaxoSmithKline's ID CEDD. "We recognize the issues created by resistance to available medicines and are determined to take advantage of novel approaches that offer new prospects for treatments across a range of infectious diseases. Anacor's boron-based chemistry has shown promise in inhibiting targets that are difficult to address with traditional carbon-based molecules and we look forward to further exploring its potential to provide new antiviral and antibiotic options."

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanc
'/>"/>

SOURCE Anacor Pharmaceuticals Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Biomedical Alliance about more than stem cells
5. Doyle seeks $2.5M for biomedical alliance
6. Alliance looks to create the right chemistry in SE Wisconsin
7. Biomedical alliance marks first full year
8. New alliance to provide Wi-Fi network for City of Madison
9. Budget axe could cut SE Wisconsin tech alliance funding
10. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
11. Milwaukee research alliance sees need for incubator